Healthcare solutions company Johnson & Johnson (NYSE: JNJ) announced on Friday that it has submitted applications to the US FDA and European Medicines Agency for approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a subcutaneous monotherapy for high-risk smoldering multiple myeloma.
If approved, DARZALEX FASPRO will be the first treatment to address this precursor stage of active multiple myeloma, aiming to intervene before symptom onset and organ damage.
Supporting data comes from the Phase 3 AQUILA study (NCT03301220), assessing DARZALEX FASPRO against active monitoring. The study's primary focus is progression-free survival, involving 390 patients diagnosed within the past five years without prior treatment exposure.
Results will be presented at the 2024 ASH Annual Meeting in San Diego from 7-10 December.
Smoldering multiple myeloma, detected in 15% of newly diagnosed cases, often progresses to active disease within two years. DARZALEX FASPRO, approved in 2020, has nine indications for multiple myeloma treatment.
DARZALEX, launched in 2015, is the first CD38-directed antibody for multiple myeloma, utilised globally in over 518,000 patients.
MicuRx completes Phase III trial for MRX-4 for injection in China
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children